vs
Assertio Holdings, Inc.（ASRT）与GENCOR INDUSTRIES INC（GENC）财务数据对比。点击上方公司名可切换其他公司
GENCOR INDUSTRIES INC的季度营收约是Assertio Holdings, Inc.的1.7倍（$23.6M vs $13.5M），GENCOR INDUSTRIES INC同比增速更快（-25.0% vs -57.9%），过去两年GENCOR INDUSTRIES INC的营收复合增速更高（-23.9% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
Gencor Industries Inc是一家重型基建设备制造商，主打沥青生产装置、热力燃烧系统及配套道路施工机械，主要服务北美及全球建筑市场，客户涵盖公共基建项目方和私营建筑运营商。
ASRT vs GENC — 直观对比
营收规模更大
GENC
是对方的1.7倍
$13.5M
营收增速更快
GENC
高出33.0%
-57.9%
两年增速更快
GENC
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $23.6M |
| 净利润 | — | $3.4M |
| 毛利率 | — | 28.7% |
| 营业利润率 | -86.7% | 13.2% |
| 净利率 | — | 14.6% |
| 营收同比 | -57.9% | -25.0% |
| 净利润同比 | — | -9.8% |
| 每股收益（稀释后） | $-4.54 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTGENC
| Q4 25 | $13.5M | $23.6M | ||
| Q3 25 | $49.5M | $18.8M | ||
| Q2 25 | $29.2M | $27.0M | ||
| Q1 25 | $26.5M | $38.2M | ||
| Q4 24 | $32.2M | $31.4M | ||
| Q3 24 | $29.2M | $20.9M | ||
| Q2 24 | $31.1M | $25.6M | ||
| Q1 24 | $32.4M | $40.7M |
净利润ASRTGENC
| Q4 25 | — | $3.4M | ||
| Q3 25 | $11.4M | $1.9M | ||
| Q2 25 | $-16.4M | $3.8M | ||
| Q1 25 | $-13.5M | $6.1M | ||
| Q4 24 | — | $3.8M | ||
| Q3 24 | $-2.9M | $1.5M | ||
| Q2 24 | $-3.7M | $2.6M | ||
| Q1 24 | $-4.5M | $6.2M |
毛利率ASRTGENC
| Q4 25 | — | 28.7% | ||
| Q3 25 | — | 24.2% | ||
| Q2 25 | — | 26.5% | ||
| Q1 25 | — | 29.7% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 25.6% | ||
| Q2 24 | — | 23.9% | ||
| Q1 24 | — | 30.3% |
营业利润率ASRTGENC
| Q4 25 | -86.7% | 13.2% | ||
| Q3 25 | 23.2% | -1.2% | ||
| Q2 25 | -27.5% | 11.6% | ||
| Q1 25 | -50.0% | 17.0% | ||
| Q4 24 | -41.9% | 14.7% | ||
| Q3 24 | -10.4% | 5.9% | ||
| Q2 24 | -11.6% | 7.8% | ||
| Q1 24 | -13.4% | 17.4% |
净利率ASRTGENC
| Q4 25 | — | 14.6% | ||
| Q3 25 | 23.1% | 10.2% | ||
| Q2 25 | -56.0% | 14.2% | ||
| Q1 25 | -51.1% | 16.0% | ||
| Q4 24 | — | 12.1% | ||
| Q3 24 | -10.0% | 6.9% | ||
| Q2 24 | -11.8% | 10.0% | ||
| Q1 24 | -13.9% | 15.3% |
每股收益（稀释后）ASRTGENC
| Q4 25 | $-4.54 | $0.23 | ||
| Q3 25 | $0.11 | $0.13 | ||
| Q2 25 | $-0.17 | $0.26 | ||
| Q1 25 | $-0.14 | $0.42 | ||
| Q4 24 | $-3.28 | $0.26 | ||
| Q3 24 | $-0.03 | $0.10 | ||
| Q2 24 | $-0.04 | $0.17 | ||
| Q1 24 | $-0.05 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | $147.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $94.0M | $215.2M |
| 总资产 | $267.0M | $228.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASRTGENC
| Q4 25 | $63.4M | $147.7M | ||
| Q3 25 | $93.4M | $136.3M | ||
| Q2 25 | $98.2M | $136.0M | ||
| Q1 25 | $87.3M | $143.7M | ||
| Q4 24 | $100.1M | $130.1M | ||
| Q3 24 | $88.6M | $115.4M | ||
| Q2 24 | $88.4M | $116.6M | ||
| Q1 24 | $80.7M | $117.1M |
总债务ASRTGENC
| Q4 25 | — | — | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | — | ||
| Q1 24 | $38.6M | — |
股东权益ASRTGENC
| Q4 25 | $94.0M | $215.2M | ||
| Q3 25 | $105.8M | $211.8M | ||
| Q2 25 | $93.3M | $209.9M | ||
| Q1 25 | $108.5M | $206.1M | ||
| Q4 24 | $121.1M | $200.0M | ||
| Q3 24 | $130.5M | $196.1M | ||
| Q2 24 | $132.2M | $194.7M | ||
| Q1 24 | $134.5M | $192.1M |
总资产ASRTGENC
| Q4 25 | $267.0M | $228.9M | ||
| Q3 25 | $319.8M | $222.6M | ||
| Q2 25 | $273.8M | $220.2M | ||
| Q1 25 | $286.4M | $223.9M | ||
| Q4 24 | $284.7M | $218.2M | ||
| Q3 24 | $276.0M | $208.1M | ||
| Q2 24 | $279.4M | $201.8M | ||
| Q1 24 | $282.0M | $206.0M |
负债/权益比ASRTGENC
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $11.1M |
| 自由现金流经营现金流 - 资本支出 | — | $10.1M |
| 自由现金流率自由现金流/营收 | — | 43.0% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | — | 3.23× |
| 过去12个月自由现金流最近4个季度 | — | $-3.2M |
8季度趋势，按日历期对齐
经营现金流ASRTGENC
| Q4 25 | $-30.0M | $11.1M | ||
| Q3 25 | $-4.8M | $-275.0K | ||
| Q2 25 | $19.1M | $-23.9M | ||
| Q1 25 | $-12.5M | $12.4M | ||
| Q4 24 | $11.5M | $14.8M | ||
| Q3 24 | $-35.0K | $-3.2M | ||
| Q2 24 | $7.4M | $-1.0M | ||
| Q1 24 | $7.5M | $11.7M |
自由现金流ASRTGENC
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | $-24.4M | ||
| Q1 25 | — | $12.3M | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | — | $-3.3M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | — | $11.7M |
自由现金流率ASRTGENC
| Q4 25 | — | 43.0% | ||
| Q3 25 | — | -6.8% | ||
| Q2 25 | — | -90.4% | ||
| Q1 25 | — | 32.2% | ||
| Q4 24 | — | 46.1% | ||
| Q3 24 | — | -15.8% | ||
| Q2 24 | — | -5.6% | ||
| Q1 24 | — | 28.7% |
资本支出强度ASRTGENC
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.0% |
现金转化率ASRTGENC
| Q4 25 | — | 3.23× | ||
| Q3 25 | -0.42× | -0.14× | ||
| Q2 25 | — | -6.24× | ||
| Q1 25 | — | 2.04× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | -2.22× | ||
| Q2 24 | — | -0.41× | ||
| Q1 24 | — | 1.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
GENC
暂无分部数据
